CHENGDU KANGHONG PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.84 CNY | +0.22% |
|
-3.67% | +23.86% |
| Apr. 29 | Kanghong Pharmaceutical's Unit Gets US FDA's Green Light to Test Macular Degeneration Drug | MT |
| Apr. 29 | Kanghong Pharmaceutical's Unit Gets Nod to Trial Macular Degeneration Drug | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +23.86% | 2.9B | D- | ||
| +37.11% | 723B | C+ | ||
| +31.11% | 598B | B | ||
| -3.21% | 364B | C+ | ||
| +20.10% | 331B | B- | ||
| +4.06% | 288B | C+ | ||
| +15.98% | 244B | B+ | ||
| +9.82% | 210B | B- | ||
| -5.11% | 208B | A+ | ||
| +8.65% | 169B | C+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 002773 Stock
- Ratings Chengdu Kanghong Pharmaceutical Group Co., Ltd